Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lacosamide - UCB

Next Previous
Drug Profile

Lacosamide - UCB

Alternative Names: ADD 234037; Erlosamide; Harkoseride; SPM 927; SPM 929; Vimpat; VIMPATÒ

Latest Information Update: 12 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Houston
  • Developer Daiichi Sankyo Company; Duke University; UCB
  • Class Acetamides; Analgesics; Antiepileptic drugs; Benzene derivatives; Neuroprotectants; Small molecules
  • Mechanism of Action CRMP2 protein modulators; Glycine gated NMDA receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies; Tonic-clonic epilepsy
  • Phase III Generalised seizures
  • Phase II/III Epilepsy; Neonatal seizures
  • Phase II Seizures
  • No development reported Essential tremor; Fibromyalgia; Osteoarthritis; Pain; Sleep disorders
  • Discontinued Migraine; Neuropathic pain

Most Recent Events

  • 12 Feb 2025 UCB Biopharma completes the phase III extention trial for Epilepsy in Hungary, Georgia, Moldova, Romania, Taiwan and Ukraine (NCT04627285)
  • 30 Nov 2024 NeuroGen Pharma enters into an asset purchase agreement with UCB for lacosamide in China
  • 31 Oct 2024 UCB Biopharma terminates phase II/III clinical trials in Neonatal seizures (Treatment-experienced) in USA, Australia, Canada (PO & IV) (NCT04519645)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top